Hormone treatment-related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

被引：0
|
作者：
Fizazi, K. [1 ]
Shore, N. [2 ]
Smith, M. [3 ]
Carles, J. [4 ]
Lebret, T. [5 ]
Lietuvietis, V. [6 ]
Mahammedi, H. [7 ]
Rannikko, A. [8 ]
Vjaters, E. [9 ]
Werbrouck, P. [10 ]
Miskic, M. [11 ]
Kuss, I. [12 ]
Le Berre, M. [13 ]
Borghesi, G. [14 ]
Sarapohja, T. [15 ]
Fayerabend, S. [16 ]
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Paris, France
[2] Carolina Urol Res Ctr, Atlant Urol Clin, Myrtle Beach, SC USA
[3] Massachusetts Gen Hosp, Genitourinary Canc Ctr, Boston, MA 02114 USA
[4] Vall dHebron Inst Oncol, Dept Oncol, Barcelona, Spain
[5] Hosp FOCH, Dept Urol & Renal Transplantat, Suresnes, France
[6] Riga Eastern Clin Univ Hosp, Urol Clin, Riga, Latvia
[7] Jean Perrin Ctr, Dept Med Oncol, Clermont Ferrand, France
[8] Helsinki Univ Hosp Comprehens Canc Ctr, Dept Urol, Helsinki, Finland
[9] P Stradins Clin Univ Hosp, Urol Ctr, Riga, Latvia
[10] AZ Groeninge, Urol Ctr, Kortrijk, Belgium
[11] Bayer Consumer Care AG, Dept Oncol, Basel, Switzerland
[12] Bayer AG, Dept Clin Dev Oncol, Berlin, Germany
[13] Bayer Healthcare SAS, Dept Clin Stat, Loos, France
[14] Bayer AG, Dept TA Oncol, Berlin, Germany
[15] Orion Corp, Orion Pharma, Espoo, Finland
[16] Studienpraxis Urol, Dept Urooncol, Nuertigen, Germany
来源：
EUROPEAN UROLOGY | 2021年 / 79卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P1226
引用
收藏
页码：S1740 / S1741
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
    Hiroji Uemura
    Hisashi Matsushima
    Kazuki Kobayashi
    Hiroya Mizusawa
    Hiroaki Nishimatsu
    Karim Fizazi
    Matthew Smith
    Neal Shore
    Teuvo Tammela
    Ken-ichi Tabata
    Nobuaki Matsubara
    Masahiro Iinuma
    Hirotsugu Uemura
    Mototsugu Oya
    Tetsuo Momma
    Mutsushi Kawakita
    Satoshi Fukasawa
    Tadahiro Kobayashi
    Iris Kuss
    Marie-Aude Le Berre
    Amir Snapir
    Toni Sarapohja
    Kazuhiro Suzuki
    International Journal of Clinical Oncology, 2021, 26 : 578 - 590
  • [32] PROSTATE-SPECIFIC ANTIGEN (PSA) OUTCOMES IN PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) TREATED WITH APALUTAMIDE (APA): RESULTS FROM PHASE 3 SPARTAN STUDY
    Small, Eric J.
    Lee, Ji Youl
    Lopez-Gitlitz, Angela
    Saad, Fred
    Rooney, Brendan
    Hadaschik, Boris A.
    Uemura, Hiroji
    Shu, Youyi
    Yu, Margaret
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E232 - E232
  • [33] Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study
    Smith, M. R.
    Saad, F.
    Chowdhury, S.
    Oudard, S.
    Hadaschik, B. A.
    Graff, J. N.
    Olmos, D.
    Mainwaring, P. N.
    Lee, J. Y.
    Uemura, H.
    De Porre, P.
    Smith, A.
    Zhang, K.
    Lopez-Gitlitz, A.
    Small, E. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 325 - 325
  • [34] Androgen Receptor (AR) anomalies and efficacy of apalutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
    Mainwaring, Paul N.
    Smith, Matthew R.
    Thomas, Shibu
    Chowdhury, Simon
    Olmos, David
    Li, Jinhui
    Oudard, Siephane
    Feng, Felix Y.
    Gormley, Michael
    Ricci, Deborah S.
    Rooney, Brendan
    Lopez-Gitlitz, Angela
    Yu, Margaret K.
    Small, Eric J.
    BJU INTERNATIONAL, 2018, 122 : 6 - 7
  • [35] Effects of prior local therapy by radical prostatectomy or radiotherapy on the efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer from aramis
    Saar, M.
    Fizazi, K.
    Shore, N. D.
    Smith, M. R.
    Damber, J-E
    Semenov, A.
    Ribal Caparros, M. J.
    Birtle, A.
    Rigaud, J.
    Ortiz, J.
    Schmall, A.
    Srinivasan, S.
    Verholen, F.
    EUROPEAN UROLOGY, 2022, 81 : S1423 - S1424
  • [36] Darolutamide (D), enzalutamide (E) and apalutamide (A), the risk of adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC): Number needed to harm (NNH)
    George, D. J.
    Waldeck, A. R.
    Guo, H.
    Upton, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S520 - S521
  • [37] Association between urinary, bowel, and hormonal treatment-related symptoms and clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC): PROSPER study.
    Saad, Fred
    Morlock, Robert
    Ivanescu, Cristina
    Sugg, Jennifer
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [38] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF THE EFFICACY AND TOLERABILITY OF APALUTAMIDE AND DAROLUTAMIDE FOR THE TREATMENT OF NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
    Chowdhury, S.
    Oudard, S.
    Uemura, H.
    Joniau, S.
    Liu, J.
    Dearden, L.
    Sermon, J.
    Van Sanden, S.
    Diels, J.
    Hadaschik, B. A.
    VALUE IN HEALTH, 2019, 22 : S407 - S407
  • [39] Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial.
    Smith, Matthew Raymond
    Saad, Fred
    Rathkopf, Dana E.
    Hadaschik, Boris A.
    Chowdhury, Simon
    Yu, Margaret K.
    Lopez-Gitlitz, Angela
    Rooney, Oliver Brendan
    Darif, Mohamed
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Small, Eric Jay
    Saad, Fred
    Chowdhury, Simon
    Hadaschik, Boris A.
    Graff, Julie Nicole
    Olmos, David
    Mainwaring, Paul N.
    Uemura, Hiroji
    Lopez-Gitlitz, Angela
    Trudel, Geralyn Carol
    Espina, Byron M.
    Shu, Youyi
    Park, Youn C.
    Rackoff, Wayne R.
    Yu, Margaret K.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345